Sign in
TerminatedPhase 1

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Finland, Germany, Israel, Japan, Singapore, South Korea, and Spain8 sites in 7 countriesChoose a country to see its sites
Status
Terminated
Phase
Phase 1
People taking part
25 people enrolled
Started
7 Sept 2020
Ended
5 Sept 2024
Type of study
Interventional
Treatments tested
  • JBH492
Record updated
10 October 2025
Why it stopped
Business, strategic, and development considerations and not due to any safety concerns

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • For patients with CLL:
  • Confirmed diagnosis of chronic lymphocytic leukemia (CLL); For patients with NHL:
  • Histologically confirmed diagnosis of B- or T-cell non-Hodgkins lymphoma (NHL)
  • Must have a site of disease amenable to biopsy, and be suitable and willing to undergo study required biopsies at screening and during therapy

Who cannot take part

  • Any prior history of treatment with maytansine (DM1 or DM4)-based ADC
  • Patients with active CNS involvement are excluded, except if the CNS involvement has been effectively treated and provided that local treatment was completed >4 weeks before first dose of study treatment. Patients that have been effectively treated for CNS disease and are stable under systemic therapy may be enrolled provided all other inclusion and exclusion criteria are met. Patients who received prophylactic intrathecal treatment are eligible, if treatment discontinued >5 half-lives prior to the first dose of study treatment
  • History of anaphylactic or other severe hypersensitivity/infusion reactions to ADCs, monoclonal antibodies (mAbs) and/or their excipients such that the patient in unable to tolerate immunoglobulin/monoclonal antibody administration
  • Patients with any active or chronic corneal disorders
  • Patients who have any other condition that precludes monitoring of the retina or fundus
  • Impaired cardiac function or clinically significant cardiac disease
  • Known history of Human Immunodeficiency Virus (HIV) infection
  • Active HBV or HCV infection. Patients whose disease is controlled under antiviral therapy should not be excluded. Patients who are anti-HBcAb positive should be HBsAg negative and HBV-DNA negative to be eligible; Other inclusion and exclusion criteria may apply
  • Known intolerance to a maytansinoid

This trial has no sites in United States.

It has sites in 7 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of the First-In-Human study was to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

The group in the trial

  • JBH492 single agentTreatment being tested

    Patients with R/R CLL or NHL

    Treatment: JBH492

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Record updated
10 October 2025